[Coagulation activity of circulating membrane microparticles in patients with cardiovascular diseases].

Q3 Biochemistry, Genetics and Molecular Biology
O A Antonova, N V Golubeva, V V Yakushkin, I T Zyuryaev, E N Krivosheeva, A L Komarov, T V Martynyuk, A V Mazurov
{"title":"[Coagulation activity of circulating membrane microparticles in patients with cardiovascular diseases].","authors":"O A Antonova,&nbsp;N V Golubeva,&nbsp;V V Yakushkin,&nbsp;I T Zyuryaev,&nbsp;E N Krivosheeva,&nbsp;A L Komarov,&nbsp;T V Martynyuk,&nbsp;A V Mazurov","doi":"10.18097/PBMC20226804288","DOIUrl":null,"url":null,"abstract":"<p><p>Membrane microparticles (MP) are released by activated or damaged cells and are able to accelerate blood clotting (coagulation). MP possess coagulation activity since all of them contain on their surface phosphatidylserine (PS), a substrate for the assembly of coagulation complexes, and some of them tissue factor (TF), the primary initiator of coagulation cascade reactions. We compared the coagulation activity and amount of MP in the blood of healthy donors (n=34) and patients with myocardial infarction (MI) (n=32), advanced atherosclerosis (AA) (n=32) and idiopathic pulmonary arterial hypertension (IPAH) (n=19). Total MP fraction was obtained from blood plasma by sedimentation at 20000 g, 30 min. The coagulation activity of PM isolated from 100 μl of donor and patient plasma was determined using a modified recalcification test. MP were added to substrate plasma devoid of endogenous MF, plasma was recalcified, and clotting was recorded by changes in optical density (A450), determining lag phase (min) and maximum rate (Vmax, %A450/min). MP were counted by flow cytometry as PS+ particles (lactadgerin-FITC staining) smaller than 1 μm and their concentration was expressed as 105 MP/μl plasma. MP in all patient groups accelerated plasma clotting more effectively than donor MP. Lag phase compared with donors (11.8 [11.0-13.1] median and interquartile range) was shorter in patients with AA (8.8 [7.0-10.3], p.</p>","PeriodicalId":8889,"journal":{"name":"Biomeditsinskaya khimiya","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomeditsinskaya khimiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18097/PBMC20226804288","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

Membrane microparticles (MP) are released by activated or damaged cells and are able to accelerate blood clotting (coagulation). MP possess coagulation activity since all of them contain on their surface phosphatidylserine (PS), a substrate for the assembly of coagulation complexes, and some of them tissue factor (TF), the primary initiator of coagulation cascade reactions. We compared the coagulation activity and amount of MP in the blood of healthy donors (n=34) and patients with myocardial infarction (MI) (n=32), advanced atherosclerosis (AA) (n=32) and idiopathic pulmonary arterial hypertension (IPAH) (n=19). Total MP fraction was obtained from blood plasma by sedimentation at 20000 g, 30 min. The coagulation activity of PM isolated from 100 μl of donor and patient plasma was determined using a modified recalcification test. MP were added to substrate plasma devoid of endogenous MF, plasma was recalcified, and clotting was recorded by changes in optical density (A450), determining lag phase (min) and maximum rate (Vmax, %A450/min). MP were counted by flow cytometry as PS+ particles (lactadgerin-FITC staining) smaller than 1 μm and their concentration was expressed as 105 MP/μl plasma. MP in all patient groups accelerated plasma clotting more effectively than donor MP. Lag phase compared with donors (11.8 [11.0-13.1] median and interquartile range) was shorter in patients with AA (8.8 [7.0-10.3], p.

[心血管疾病患者循环膜微粒的凝血活性]。
膜微粒(MP)由活化或受损细胞释放,能够加速血液凝固(凝血)。MP具有凝血活性,因为它们的表面都含有用于凝血复合物组装的底物磷脂酰丝氨酸(PS)和一些组织因子(TF),后者是凝血级联反应的主要引发剂。我们比较了健康献血者(n=34)和心肌梗死(n=32)、晚期动脉粥样硬化(n=32)和特发性肺动脉高压(n=19)患者血液中的凝血活性和MP含量。在20000g、30min的条件下,从血浆中提取总MP组分,用改良的再钙化试验测定供者和患者血浆中各100 μl PM的凝血活性。将MP添加到缺乏内源性MF的底物血浆中,血浆再钙化,通过光密度(A450)的变化记录凝血,确定滞后期(min)和最大速率(Vmax, %A450/min)。流式细胞术计数MP为小于1 μm的PS+颗粒(lactadgerin-FITC染色),其浓度表示为105 MP/μl血浆。在所有患者组中,MP均比供体MP更有效地加速血浆凝血。与献血者相比,AA患者的滞后期(11.8[11.0-13.1]中位数和四分位数范围)更短(8.8 [7.0-10.3],p。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Biomeditsinskaya khimiya
Biomeditsinskaya khimiya Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)
CiteScore
1.30
自引率
0.00%
发文量
49
期刊介绍: The aim of the Russian-language journal "Biomeditsinskaya Khimiya" (Biomedical Chemistry) is to introduce the latest results obtained by scientists from Russia and other Republics of the Former Soviet Union. The Journal will cover all major areas of Biomedical chemistry, including neurochemistry, clinical chemistry, molecular biology of pathological processes, gene therapy, development of new drugs and their biochemical pharmacology, introduction and advertisement of new (biochemical) methods into experimental and clinical medicine etc. The Journal also publish review articles. All issues of journal usually contain invited reviews. Papers written in Russian contain abstract (in English).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信